Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1983-02-24
1985-01-15
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
260112R, 260115, 260121, 2601235, 260112B, C07G 704
Patent
active
044938292
ABSTRACT:
The invention relates to succinylated proteins, with a degree of succinylation of between 20 to 100%, containing from 0.1 to 20% by weight of iron, obtained by treating succinylated proteins with iron salts in suitable pH ranges. The compounds in question, which are completely tolerated, are characterized by an optimum bioavailability of iron.
REFERENCES:
patent: 2932589 (1960-04-01), Meyer et al.
patent: 3712865 (1973-01-01), Evans et al.
patent: 3756682 (1973-09-01), Huber et al.
patent: 3764711 (1973-09-01), Melnychyn et al.
patent: 3873296 (1975-03-01), Ashmead et al.
patent: 4017605 (1977-04-01), Huber et al.
patent: 4020158 (1977-04-01), Ashmead et al.
patent: 4172072 (1979-10-01), Ashmead
patent: 4208405 (1980-06-01), Fouad
patent: 4216144 (1980-08-01), Ashmead
patent: 4411915 (1983-10-01), Eriksson
Cremonesi Pietro
Pagella Piergiuseppe
Sportoletti Giancarlo
Italfarmaco S.p.A.
Schain Howard E.
Schneider Walter H.
LandOfFree
Bio-available succinylated protein-iron derivatives which do not does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bio-available succinylated protein-iron derivatives which do not, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bio-available succinylated protein-iron derivatives which do not will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1481004